Journal of Pathology and Translational Medicine

Original Article

Interobserver Reproducibility of PD-L1 Biomarker in Non-small Cell Lung Cancer: A Multi-Institutional Study by 27 Pathologists: Sunhee Chang, Hyung Kyu Park, Yoon-La Choi, Se Jin Jang; J Pathol Transl Med. 2019;53(6):347-353. Published online October 28, 2019; DOI: https://doi.org/10.4132/jptm.2019.09.29

5,340 View
196 Download
24 Web of Science
24 Crossref

Background
Assessment of programmed cell death-ligand 1 (PD-L1) immunohistochemical staining is used for treatment decisions in non-small cell lung cancer (NSCLC) regarding use of PD-L1/programmed cell death protein 1 (PD-1) immunotherapy. The reliability of the PD-L1 22C3 pharmDx assay is critical in guiding clinical practice. The Cardiopulmonary Pathology Study Group of the Korean Society of Pathologists investigated the interobserver reproducibility of PD-L1 staining with 22C3 pharmDx in NSCLC samples.
Methods
Twenty-seven pathologists individually assessed the tumor proportion score (TPS) for 107 NSCLC samples. Each case was divided into three levels based on TPS: <1%, 1%–49%, and ≥50%.
Results
The intraclass correlation coefficient for TPS was 0.902±0.058. Weighted κ coefficient for 3-step assessment was 0.748±0.093. The κ coefficients for 1% and 50% cut-offs were 0.633 and 0.834, respectively. There was a significant association between interobserver reproducibility and experience (formal PD-L1 training, more experience for PD-L1 assessment, and longer practice duration on surgical pathology), histologic subtype, and specimen type.
Conclusions
Our results indicate that PD-L1 immunohistochemical staining provides a reproducible basis for decisions on anti–PD-1 therapy in NSCLC.

Citations

Citations to this article as recorded by

Weakly Supervised Deep Learning Predicts Immunotherapy Response in Solid Tumors Based on PD-L1 Expression
Marta Ligero, Garazi Serna, Omar S.M. El Nahhas, Irene Sansano, Siarhei Mauchanski, Cristina Viaplana, Julien Calderaro, Rodrigo A. Toledo, Rodrigo Dienstmann, Rami S. Vanguri, Jennifer L. Sauter, Francisco Sanchez-Vega, Sohrab P. Shah, Santiago Ramón y C
Cancer Research Communications.2024; 4(1): 92. CrossRef
Concordance of assessments of four PD-L1 immunohistochemical assays in esophageal squamous cell carcinoma (ESCC)
Xinran Wang, Jiankun He, Jinze Li, Chun Wu, Meng Yue, Shuyao Niu, Ying Jia, Zhanli Jia, Lijing Cai, Yueping Liu
Journal of Cancer Research and Clinical Oncology.2024;[Epub] CrossRef
Deep learning-based assay for programmed death ligand 1 immunohistochemistry scoring in non-small cell lung carcinoma: Does it help pathologists score?
Hiroaki Ito, Akihiko Yoshizawa, Kazuhiro Terada, Akiyoshi Nakakura, Mariyo Rokutan-Kurata, Tatsuhiko Sugimoto, Kazuya Nishimura, Naoki Nakajima, Shinji Sumiyoshi, Masatsugu Hamaji, Toshi Menju, Hiroshi Date, Satoshi Morita, Ryoma Bise, Hironori Haga
Modern Pathology.2024; : 100485. CrossRef
Impact of Prolonged Ischemia on the Immunohistochemical Expression of Programmed Death Ligand 1 (PD-L1)
Angels Barberà, Juan González, Montserrat Martin, Jose L. Mate, Albert Oriol, Fina Martínez-Soler, Tomas Santalucia, Pedro Luis Fernández
Applied Immunohistochemistry & Molecular Morphology.2023; 31(9): 607. CrossRef
A practical approach for PD-L1 evaluation in gastroesophageal cancer
Valentina Angerilli, Matteo Fassan, Paola Parente, Irene Gullo, Michela Campora, Chiara Rossi, Maria Luisa Sacramento, Gianmaria Pennelli, Alessandro Vanoli, Federica Grillo, Luca Mastracci
Pathologica.2023; 115(2): 57. CrossRef
EZH2 and POU2F3 Can Aid in the Distinction of Thymic Carcinoma from Thymoma
Julia R. Naso, Julie A. Vrana, Justin W. Koepplin, Julian R. Molina, Anja C. Roden
Cancers.2023; 15(8): 2274. CrossRef
Artificial intelligence-assisted system for precision diagnosis of PD-L1 expression in non-small cell lung cancer
Jianghua Wu, Changling Liu, Xiaoqing Liu, Wei Sun, Linfeng Li, Nannan Gao, Yajun Zhang, Xin Yang, Junjie Zhang, Haiyue Wang, Xinying Liu, Xiaozheng Huang, Yanhui Zhang, Runfen Cheng, Kaiwen Chi, Luning Mao, Lixin Zhou, Dongmei Lin, Shaoping Ling
Modern Pathology.2022; 35(3): 403. CrossRef
Immunohistochemistry as predictive and prognostic markers for gastrointestinal malignancies
Matthew W. Rosenbaum, Raul S. Gonzalez
Seminars in Diagnostic Pathology.2022; 39(1): 48. CrossRef
Gastric Cancer: Mechanisms, Biomarkers, and Therapeutic Approaches
Sangjoon Choi, Sujin Park, Hyunjin Kim, So Young Kang, Soomin Ahn, Kyoung-Mee Kim
Biomedicines.2022; 10(3): 543. CrossRef
Development and validation of a supervised deep learning algorithm for automated whole‐slide programmed death‐ligand 1 tumour proportion score assessment in non‐small cell lung cancer
Liesbeth M Hondelink, Melek Hüyük, Pieter E Postmus, Vincent T H B M Smit, Sami Blom, Jan H von der Thüsen, Danielle Cohen
Histopathology.2022; 80(4): 635. CrossRef
5-hmC loss is another useful tool in addition to BAP1 and MTAP immunostains to distinguish diffuse malignant peritoneal mesothelioma from reactive mesothelial hyperplasia in peritoneal cytology cell-blocks and biopsies
Ziyad Alsugair, Vahan Kepenekian, Tanguy Fenouil, Olivier Glehen, Laurent Villeneuve, Sylvie Isaac, Juliette Hommell-Fontaine, Nazim Benzerdjeb
Virchows Archiv.2022; 481(1): 23. CrossRef
Artificial intelligence–powered programmed death ligand 1 analyser reduces interobserver variation in tumour proportion score for non–small cell lung cancer with better prediction of immunotherapy response
Sangjoon Choi, Soo Ick Cho, Minuk Ma, Seonwook Park, Sergio Pereira, Brian Jaehong Aum, Seunghwan Shin, Kyunghyun Paeng, Donggeun Yoo, Wonkyung Jung, Chan-Young Ock, Se-Hoon Lee, Yoon-La Choi, Jin-Haeng Chung, Tony S. Mok, Hyojin Kim, Seokhwi Kim
European Journal of Cancer.2022; 170: 17. CrossRef
Artificial Intelligence-Assisted Score Analysis for Predicting the Expression of the Immunotherapy Biomarker PD-L1 in Lung Cancer
Guoping Cheng, Fuchuang Zhang, Yishi Xing, Xingyi Hu, He Zhang, Shiting Chen, Mengdao Li, Chaolong Peng, Guangtai Ding, Dadong Zhang, Peilin Chen, Qingxin Xia, Meijuan Wu
Frontiers in Immunology.2022;[Epub] CrossRef
Association of artificial intelligence-powered and manual quantification of programmed death-ligand 1 (PD-L1) expression with outcomes in patients treated with nivolumab ± ipilimumab
Vipul Baxi, George Lee, Chunzhe Duan, Dimple Pandya, Daniel N. Cohen, Robin Edwards, Han Chang, Jun Li, Hunter Elliott, Harsha Pokkalla, Benjamin Glass, Nishant Agrawal, Abhik Lahiri, Dayong Wang, Aditya Khosla, Ilan Wapinski, Andrew Beck, Michael Montalt
Modern Pathology.2022; 35(11): 1529. CrossRef
High interobserver and intraobserver reproducibility among pathologists assessing PD‐L1 CPS across multiple indications
Shanthy Nuti, Yiwei Zhang, Nabila Zerrouki, Charlotte Roach, Gudrun Bänfer, George L Kumar, Edward Manna, Rolf Diezko, Kristopher Kersch, Josef Rüschoff, Bharat Jasani
Histopathology.2022; 81(6): 732. CrossRef
Modifying factors of PD‐L1 expression on tumor cells in advanced non‐small‐cell lung cancer
Alejandro Avilés‐Salas, Diana Flores‐Estrada, Luis Lara‐Mejía, Rodrigo Catalán, Graciela Cruz‐Rico, Mario Orozco‐Morales, David Heredia, Laura Bolaño‐Guerra, Pamela Denisse Soberanis‐Piña, Edgar Varela‐Santoyo, Andrés F. Cardona, Oscar Arrieta
Thoracic Cancer.2022; 13(23): 3362. CrossRef
Comparability of laboratory-developed and commercial PD-L1 assays in non-small cell lung carcinoma
Julia R. Naso, Gang Wang, Norbert Banyi, Fatemeh Derakhshan, Aria Shokoohi, Cheryl Ho, Chen Zhou, Diana N. Ionescu
Annals of Diagnostic Pathology.2021; 50: 151590. CrossRef
Interobserver agreement in programmed cell death‐ligand 1 immunohistochemistry scoring in nonsmall cell lung carcinoma cytologic specimens
William Sinclair, Peter Kobalka, Rongqin Ren, Boulos Beshai, Abberly A. Lott Limbach, Lai Wei, Ping Mei, Zaibo Li
Diagnostic Cytopathology.2021; 49(2): 219. CrossRef
Automated PD-L1 Scoring for Non-Small Cell Lung Carcinoma Using Open-Source Software
Julia R. Naso, Tetiana Povshedna, Gang Wang, Norbert Banyi, Calum MacAulay, Diana N. Ionescu, Chen Zhou
Pathology and Oncology Research.2021;[Epub] CrossRef
The Immunohistochemical Expression of Programmed Death Ligand 1 (PD-L1) Is Affected by Sample Overfixation
Angels Barberà, Ruth Marginet Flinch, Montserrat Martin, Jose L. Mate, Albert Oriol, Fina Martínez-Soler, Tomas Santalucia, Pedro L. Fernández
Applied Immunohistochemistry & Molecular Morphology.2021; 29(1): 76. CrossRef
Programmed cell death-ligand 1 assessment in urothelial carcinoma: prospect and limitation
Kyu Sang Lee, Gheeyoung Choe
Journal of Pathology and Translational Medicine.2021; 55(3): 163. CrossRef
Comparison of Semi-Quantitative Scoring and Artificial Intelligence Aided Digital Image Analysis of Chromogenic Immunohistochemistry
János Bencze, Máté Szarka, Balázs Kóti, Woosung Seo, Tibor G. Hortobágyi, Viktor Bencs, László V. Módis, Tibor Hortobágyi
Biomolecules.2021; 12(1): 19. CrossRef
Immunization against ROS1 by DNA Electroporation Impairs K-Ras-Driven Lung Adenocarcinomas
Federica Riccardo, Giuseppina Barutello, Angela Petito, Lidia Tarone, Laura Conti, Maddalena Arigoni, Chiara Musiu, Stefania Izzo, Marco Volante, Dario Livio Longo, Irene Fiore Merighi, Mauro Papotti, Federica Cavallo, Elena Quaglino
Vaccines.2020; 8(2): 166. CrossRef
Utility of PD-L1 testing on non-small cell lung cancer cytology specimens: An institutional experience with interobserver variability analysis
Oleksandr Kravtsov, Christopher P. Hartley, Yuri Sheinin, Bryan C. Hunt, Juan C. Felix, Tamara Giorgadze
Annals of Diagnostic Pathology.2020; 48: 151602. CrossRef

Brief Case Report

Metastatic Squamous Cell Carcinoma from Lung Adenocarcinoma after Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy: Hyung Kyu Park, Youjeong Seo, Yoon-La Choi, Myung-Ju Ahn, Joungho Han; J Pathol Transl Med. 2017;51(4):441-443. Published online April 4, 2017; DOI: https://doi.org/10.4132/jptm.2016.10.18

6,219 View
130 Download
8 Web of Science
9 Crossref

PDF

Citations

Citations to this article as recorded by

Spontaneous histological transformation of lung squamous-cell carcinoma to large cell neuroendocrine carcinoma and small cell lung cancer
Jin-Dong Li, Cheng-Yan Jin, Yan Zhang, Hang Guo, Guang-Lei Zhang, Chun-Guang Wang
Journal of Cancer Research and Clinical Oncology.2023; 149(13): 11333. CrossRef
Morphologic-Molecular Transformation of Oncogene Addicted Non-Small Cell Lung Cancer
Fiorella Calabrese, Federica Pezzuto, Francesca Lunardi, Francesco Fortarezza, Sofia-Eleni Tzorakoleftheraki, Maria Vittoria Resi, Mariaenrica Tiné, Giulia Pasello, Paul Hofman
International Journal of Molecular Sciences.2022; 23(8): 4164. CrossRef
T790M mutation positive squamous cell carcinoma transformation from EGFR-mutated lung adenocarcinoma after low dose erlotinib: A case report and literature review
Yusaku Kusaba, Yuichiro Takeda, Sakurako Abe, Akinari Tsukada, Go Naka
Medicine.2022; 101(32): e29682. CrossRef
Case Report: EGFR-Positive Early-Stage Lung Adenocarcinoma Transforming to Squamous Cell Carcinoma After TKI Treatment
Jiatao Liao, Yuan Li, Chang Liu, Qianqian Long, Jialei Wang
Frontiers in Oncology.2021;[Epub] CrossRef
Squamous cell carcinoma transformation of lung adenocarcinoma after tyrosine kinase inhibitor therapy: Cytological approach
Alexandra Grosse, Claudia Grosse
Cytopathology.2020; 31(3): 232. CrossRef
Outcome of EGFR-mutated adenocarcinoma NSCLC patients with changed phenotype to squamous cell carcinoma after tyrosine kinase inhibitors: A pooled analysis with an additional case
Elisa Roca, Marta Pozzari, William Vermi, Valeria Tovazzi, Alice Baggi, Vito Amoroso, Daniela Nonnis, Salvatore Intagliata, Alfredo Berruti
Lung Cancer.2019; 127: 12. CrossRef
Squamous Cell Transformation of Primary Lung Adenocarcinoma in a Patient With EML4-ALK Fusion Variant 5 Refractory to ALK Inhibitors
Jay Gong, Jeffrey P. Gregg, Weijie Ma, Ken Yoneda, Elizabeth H. Moore, Megan E. Daly, Yanhong Zhang, Melissa J. Williams, Tianhong Li
Journal of the National Comprehensive Cancer Network.2019; 17(4): 297. CrossRef
Pathological transition as the arising mechanism for drug resistance in lung cancer
Yueqing Chen, Waiying Yvonne Tang, Xinyuan Tong, Hongbin Ji
Cancer Communications.2019; 39(1): 1. CrossRef
Afatinib

Reactions Weekly.2017; 1669(1): 18. CrossRef

Correspondence

Erratum: Correction of Acknowledgments. ERG Immunohistochemistry as an Endothelial Marker for Assessing Lymphovascular Invasion: Sehun Kim, Hyung Kyu Park, Ho Young Jung, So-Young Lee, Kyueng-Whan Min, Wook Youn Kim, Hye Seung Han, Wan Seop Kim, Tae Sook Hwang, So Dug Lim; Korean J Pathol. 2013;47(5):503-503. Published online October 25, 2013; DOI: https://doi.org/10.4132/KoreanJPathol.2013.47.5.503

4,444 View
39 Download

PDF

Original Article

ERG Immunohistochemistry as an Endothelial Marker for Assessing Lymphovascular Invasion: Sehun Kim, Hyung Kyu Park, Ho Young Jung, So-Young Lee, Kyueng-Whan Min, Wook Youn Kim, Hye Seung Han, Wan Seop Kim, Tae Sook Hwang, So Dug Lim; Korean J Pathol. 2013;47(4):355-364. Published online August 26, 2013; DOI: https://doi.org/10.4132/KoreanJPathol.2013.47.4.355

10,152 View
64 Download
24 Crossref

Abstract PDF

Background

ERG, a member of the ETS family of transcription factors, is a highly specific endothelial marker. We investigated whether the use of ERG immunostaining can help pathologists detect lymphovascular invasion (LVI) and decrease interobserver variability in LVI diagnosis.

Methods

Fifteen cases of surgically resected colorectal cancers with hepatic metastasis were selected and the most representative sections for LVI detection were immunostained with ERG, CD31, and D2-40. Eight pathologists independently evaluated LVI status on hematoxylin and eosin (H&E) and the corresponding immunostained sections and then convened for a consensus meeting. The results were analyzed by kappa (κ) statistics.

Results

The average rate of LVI positivity was observed in 43% with H&E only, 10% with CD31, 29% with D2-40, and 16% with ERG. Agreement among pathologists was fair for H&E only (κ=0.27), D2-40 (κ=0.21), ERG (κ=0.23), and was moderate for CD31 (κ=0.55). Consensus revealed that ERG nuclear immunoreactivity showed better visual contrast of LVI detection than the other staining, with improved agreement and LVI detection rate (κ=0.65, LVI positivity rate 80%).

Conclusions

The present study demonstrated a superiority with ERG immunostaining and indicated that ERG is a promising panendothelial marker that might help pathologists increase LVI detection and decrease interobserver variability in LVI diagnosis.

Citations

Citations to this article as recorded by

Exercise mitigates flow recirculation and activates metabolic transducer SCD1 to catalyze vascular protective metabolites
Susana Cavallero, Mehrdad Roustaei, Sandro Satta, Jae Min Cho, Henry Phan, Kyung In Baek, Ana M. Blázquez-Medela, Sheila Gonzalez-Ramos, Khoa Vu, Seul-Ki Park, Tomohiro Yokota, Jennifer Sumner, Julia J. Mack, Curt D. Sigmund, Srinivasa T. Reddy, Rongsong
Science Advances.2024;[Epub] CrossRef
Cardiac delivery of modified mRNA using lipid nanoparticles: Cellular targets and biodistribution after intramyocardial administration
M.C.I. Labonia, M. Estapé Senti, P.H. van der Kraak, M.A.D. Brans, I. Dokter, T.J. Streef, A.M. Smits, A.K. Deshantri, S.C.A. de Jager, R.M. Schiffelers, J.P.G. Sluijter, P. Vader
Journal of Controlled Release.2024; 369: 734. CrossRef
Endometrial cancer: predictors and oncological safety of tumor tissue manipulation
Raquel Quintana-Bertó, Pablo Padilla-Iserte, Víctor Lago, Carmen Tauste, Berta Díaz-Feijoo, Silvia Cabrera, Reyes Oliver-Pérez, Pluvio J. Coronado, María Belén Martín-Salamanca, Manuel Pantoja-Garrido, Josefa Marcos-Sanmartin, Eduardo Cazorla, Cristina Lo
Clinical and Translational Oncology.2023; 26(5): 1098. CrossRef
Universal method for the isolation of microvessels from frozen brain tissue: A proof-of-concept multiomic investigation of the neurovasculature
Marina Wakid, Daniel Almeida, Zahia Aouabed, Reza Rahimian, Maria Antonietta Davoli, Volodymyr Yerko, Elena Leonova-Erko, Vincent Richard, René Zahedi, Christoph Borchers, Gustavo Turecki, Naguib Mechawar
Brain, Behavior, & Immunity - Health.2023; 34: 100684. CrossRef
The Usefulness of Elastin Staining to Detect Vascular Invasion in Cancer
Jeffrey Gonzalez, Hisham F. Bahmad, Stephanie Ocejo, Alvaro Abreu, Meagan Popp, Samantha Gogola, Vielka Fernandez, Monica Recine, Robert Poppiti
International Journal of Molecular Sciences.2023; 24(20): 15264. CrossRef
Single‐nucleus transcriptome analysis reveals disease‐ and regeneration‐associated endothelial cells in white matter vascular dementia
Daniel N. Mitroi, Min Tian, Riki Kawaguchi, William E. Lowry, S. Thomas Carmichael
Journal of Cellular and Molecular Medicine.2022; 26(11): 3183. CrossRef
Gene of the month: ERG
Dorinda Mullen, Klaudia Nowak, Runjan Chetty
Journal of Clinical Pathology.2022; 75(9): 577. CrossRef
Oncological safety of hysteroscopy in endometrial cancer
Raquel Quintana-Bertó, Pablo Padilla-Iserte, Antonio Gil-Moreno, Reyes Oliver-Pérez, Pluvio J. Coronado, María Belén Martín-Salamanca, Manuel Pantoja-Garrido, Cristina Lorenzo, Eduardo Cazorla, Juan Gilabert-Estellés, Lourdes Sánchez, Fernando Roldán-Riva
International Journal of Gynecologic Cancer.2022; 32(11): 1395. CrossRef
Upregulated PD-1 signaling antagonizes glomerular health in aged kidneys and disease
Jeffrey W. Pippin, Natalya Kaverina, Yuliang Wang, Diana G. Eng, Yuting Zeng, Uyen Tran, Carol J. Loretz, Anthony Chang, Shreeram Akilesh, Chetan Poudel, Hannah S. Perry, Christopher O’Connor, Joshua C. Vaughan, Markus Bitzer, Oliver Wessely, Stuart J. Sh
Journal of Clinical Investigation.2022;[Epub] CrossRef
Primary Soft Tissue Sarcoma of the Heart: An Emerging Chapter in Cardio-Oncology
Pietro Scicchitano, Maria Chiara Sergi, Matteo Cameli, Marcelo H. Miglioranza, Marco Matteo Ciccone, Marica Gentile, Camillo Porta, Marco Tucci
Biomedicines.2021; 9(7): 774. CrossRef
Analysis on the healing of gastrointestinal ulceration by using Hemospray
Christoph R. Werner, Lena Brücklmeier, Thomas Kratt, Nisar P. Malek, Bence Sipos, Dörte Wichmann, Martin Götz
Scientific Reports.2021;[Epub] CrossRef
Immunohistochemistry for diagnosis and prognosis of breast cancer: a review
T. Bonacho, F. Rodrigues, J. Liberal
Biotechnic & Histochemistry.2020; 95(2): 71. CrossRef
TMEM100 is a key factor for specification of lymphatic endothelial progenitors
Eun-Hye Moon, Yong Hwan Kim, Phuong-Nhung Vu, Hyunjin Yoo, Kwonho Hong, Young Jae Lee, S. Paul Oh
Angiogenesis.2020; 23(3): 339. CrossRef
Spectral photon-counting CT imaging of colorectal peritoneal metastases: initial experience in rats
Arnaud Thivolet, Salim Si-Mohamed, Pierre-Emmanuel Bonnot, Christophe Blanchet, Vahan Képénékian, Loïc Boussel, Philippe Douek, Pascal Rousset
Scientific Reports.2020;[Epub] CrossRef
Diagnostic and reporting issues of preneoplastic polyps of the large intestine with early carcinoma
Dale C. Snover
Annals of Diagnostic Pathology.2019; 39: 1. CrossRef
Feasibility of Endoscopic Resection in Early Gastric Cancer with Lymphovascular Invasion
Jeung Hui Pyo, Hyuk Lee, Yang Won Min, Byung-Hoon Min, Jun Haeng Lee, Kyoung-Mee Kim, Hyeseung Kim, Kyunga Kim, Jae J. Kim
Annals of Surgical Oncology.2019; 26(2): 449. CrossRef
Lymphovascular Invasion and the Decision for Postmastectomy Radiation Therapy: A Cautionary Case Report
J. Arthur Jensen, Rania Bakkar, Michele Burnison, Armando E. Giuliano
Plastic and Reconstructive Surgery - Global Open.2019; 7(2): e2115. CrossRef
Utility of ERG Immunohistochemistry for Evaluation of Lymphovascular Invasion in Testicular Germ Cell Tumors: A Retrospective Pilot Study
Aaron M. Udager, Jonathan B. McHugh, Todd M. Morgan, Daniel E. Spratt, Arul M. Chinnaiyan, Rohit Mehra
Applied Immunohistochemistry & Molecular Morphology.2019; 27(5): 392. CrossRef
An interesting observation from our experiences with circulating tumour cells
Kok H. Lim, Yong W. Chua, Tony K.H. Lim, Angela M. Takano
Lung Cancer.2017; 108: 247. CrossRef
Differences in Prevalence of Lymphovascular Invasion among Early Gastric Cancers between Korea and Japan
Sun-Young Lee, Naohisa Yoshida, Osamu Dohi, Sang Pyo Lee, Daisuke Ichikawa, Jeong Hwan Kim, In-Kyung Sung, Hyung Seok Park, Eigo Otsuji, Yoshito Itoh, Chan Sup Shim, Hye Seung Han, Mitsuo Kishimoto, Yuji Naito
Gut and Liver.2017; 11(3): 383. CrossRef
Tumor Budding Is an Independent Adverse Prognostic Factor in Pancreatic Ductal Adenocarcinoma
Kate O’Connor, Hector H. Li-Chang, Steven E. Kalloger, Renata D. Peixoto, Douglas L. Webber, David A. Owen, David K. Driman, Richard Kirsch, Stefano Serra, Charles H. Scudamore, Daniel J. Renouf, David F. Schaeffer
American Journal of Surgical Pathology.2015; 39(4): 472. CrossRef
P2X7Receptor Expression in Coexistence of Papillary Thyroid Carcinoma with Hashimoto's Thyroiditis
Ji Hyun Kwon, Eun Sook Nam, Hyung Sik Shin, Seong Jin Cho, Hye Rim Park, Mi Jung Kwon
Korean Journal of Pathology.2014; 48(1): 30. CrossRef
Evaluation of colon cancer histomorphology: a comparison between formalin and PAXgene tissue fixation by an international ring trial
Sibylle Gündisch, Julia Slotta-Huspenina, Paolo Verderio, Chiara Maura Ciniselli, Sara Pizzamiglio, Christina Schott, Enken Drecoll, Christian Viertler, Kurt Zatloukal, Marcel Kap, Peter Riegman, Irene Esposito, Katja Specht, Gregor Babaryka, Martin Assla
Virchows Archiv.2014; 465(5): 509. CrossRef
Tumor Sprouting in Papillary Thyroid Carcinoma Is Correlated with Lymph Node Metastasis and Recurrence
Eunjung Lee, Wonkyung Jung, Jeong-Soo Woo, Jae Bok Lee, Bong Kyung Shin, Han Kyeom Kim, Aeree Kim, Baek-hui Kim
Korean Journal of Pathology.2014; 48(2): 117. CrossRef

First
Prev
Page of 1
Next
Last

Search